160 related articles for article (PubMed ID: 37138433)
1. SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review.
SeyedAlinaghi S; Karimi A; Mirzapour P; Salmani R; Razi A; Mojdeganlou H; Mojdeganlou P; Qodrati M; Jashaninejad R; Paranjkhoo P; Dadras O; Zarezadeh B; Afsahi AM; Afzalian A; Varshochi S; Mehraeen E; Afsahi G
Infect Disord Drug Targets; 2023; 23(7):29-38. PubMed ID: 37138433
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
4. Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis.
Khoury E; Nevitt S; Madsen WR; Turtle L; Davies G; Palmieri C
JAMA Netw Open; 2022 May; 5(5):e2210880. PubMed ID: 35532936
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
6. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.
Naimi A; Yashmi I; Jebeleh R; Imani Mofrad M; Azimian Abhar S; Jannesar Y; Heidary M; Pakzad R
J Clin Lab Anal; 2022 May; 36(5):e24387. PubMed ID: 35385130
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
Civriz Bozdağ S; Cengiz Seval G; Yönal Hindilerden İ; Hindilerden F; Andıç N; Baydar M; Aydın Kaynar L; Toprak SK; Göksoy HS; Balık Aydın B; Demirci U; Can F; Özkocaman V; Gündüz E; Güven ZT; Özkurt ZN; Demircioğlu S; Beksaç M; İnce İ; Yılmaz U; Eroğlu Küçükdiler H; Abishov E; Yavuz B; Ataş Ü; Mutlu YG; Baş V; Özkalemkaş F; Üsküdar Teke H; Gürsoy V; Çelik S; Çiftçiler R; Yağcı M; Topçuoğlu P; Çeneli Ö; Abbasov H; Selim C; Ar MC; Yücel OK; Sadri S; Albayrak C; Demir AM; Güler N; Keklik M; Terzi H; Doğan A; Yegin ZA; Kurt Yüksel M; Sadri S; Yavaşoğlu İ; Beköz HS; Aksu T; Maral S; Erol V; Kaynar L; İlhan O; Bolaman AZ; Sevindik ÖG; Akyay A; Özcan M; Gürman G; Ünal Ş; Yavuz Y; Diz Küçükkaya R; Özsan GH
Turk J Haematol; 2022 Feb; 39(1):43-54. PubMed ID: 34521187
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
Wang L; Wang W; Xu R; Berger NA
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.
Wood WA; Neuberg DS; Thompson JC; Tallman MS; Sekeres MA; Sehn LH; Anderson KC; Goldberg AD; Pennell NA; Niemeyer CM; Tucker E; Hewitt K; Plovnick RM; Hicks LK
Blood Adv; 2020 Dec; 4(23):5966-5975. PubMed ID: 33278301
[TBL] [Abstract][Full Text] [Related]
10. Impact of SARS-CoV-2 infection on patients with hematological malignancies: a retrospective study.
Zhao H; He Y; Li Z; Huang Y; Ying Y; Huang Z
Hematology; 2023 Dec; 28(1):2288480. PubMed ID: 38063157
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
12. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.
Tagliamento M; Agostinetto E; Bruzzone M; Ceppi M; Saini KS; de Azambuja E; Punie K; Westphalen CB; Morgan G; Pronzato P; Del Mastro L; Poggio F; Lambertini M
Crit Rev Oncol Hematol; 2021 Jul; 163():103365. PubMed ID: 34052423
[TBL] [Abstract][Full Text] [Related]
13. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
14. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.
Laracy JC; Kamboj M; Vardhana SA
Curr Opin Infect Dis; 2022 Aug; 35(4):271-279. PubMed ID: 35849516
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review.
Kim JS; Lee KH; Kim GE; Kim S; Yang JW; Li H; Hong SH; Ghayda RA; Kronbichler A; Koyanagi A; Jacob L; Shin JI; Smith L
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11926-11933. PubMed ID: 33275265
[TBL] [Abstract][Full Text] [Related]
16. Cycle threshold predicted mortality in a cohort of patients with hematologic malignancies infected with SARS-CoV-2.
Santarelli IM; Manzella DJ; Gallo Vaulet ML; Rodríguez Fermepín M; Crespo Y; Toledo Monaca S; Dobarro M; Fernández SI
Rev Argent Microbiol; 2023; 55(3):246-250. PubMed ID: 37208258
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.
Goudsmit A; Cubilier E; Meert AP; Aftimos P; Stathopoulos K; Spilleboudt C; Loizidou A
Support Care Cancer; 2021 Nov; 29(11):6271-6278. PubMed ID: 33851236
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies.
Modemann F; Niederwieser C; Weisel K; Bokemeyer C; Fiedler W; Ghandili S
Leuk Lymphoma; 2022 Mar; 63(3):664-671. PubMed ID: 34668809
[TBL] [Abstract][Full Text] [Related]
19. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.
Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G
Front Immunol; 2023; 14():1087996. PubMed ID: 37187728
[TBL] [Abstract][Full Text] [Related]
20. [SARS-COV-2 infection in patients with hematological malignancies and transplants].
Herrera F; Bues F; Rojas R; Temporiti E; Videla C; Dupont J; Bonvehí P
Medicina (B Aires); 2021; 81(3):396-400. PubMed ID: 34137699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
